Cargando…
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience
Background Ibrutinib is a Bruton’s tyrosine kinase inhibitor, which is United States Food and Drug Administration (FDA)-approved for chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström’s macroglobulinemia. Ibrutinib is associated with atrial fibrillation and bleeding events. Our aim...
Autores principales: | Khalid, Sidra, Yasar, Samin, Khalid, Aariez, Spiro, Timothy PP, Haddad, Abdo, Daw, Hamed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063389/ https://www.ncbi.nlm.nih.gov/pubmed/30062075 http://dx.doi.org/10.7759/cureus.2701 |
Ejemplares similares
-
Management of Primary Mediastinal B-Cell Lymphoma in Pregnancy
por: Khalid, Sidra, et al.
Publicado: (2018) -
Dosage Adjustments for Chemotherapy and Targeted Therapies in Colorectal and Pancreatic Cancer Patients with Hepatic Impairment
por: Khalid, Sidra, et al.
Publicado: (2018) -
Risk Factors and Management of Takotsubo Cardiomyopathy
por: Khalid, Sidra, et al.
Publicado: (2018) -
Clinical Characteristics and Outcomes of Primary Breast Lymphoma: The Cleveland Clinic Experience
por: Kewan, Tariq, et al.
Publicado: (2020) -
A Case of Postpartum Ovarian Vein Thrombosis
por: Khalid, Sidra, et al.
Publicado: (2018)